Dashboard
1
Poor Management Efficiency with a low ROCE of 2.62%
- The company has been able to generate a Return on Capital Employed (avg) of 2.62% signifying low profitability per unit of total capital (equity and debt)
2
High Debt Company with a Debt to Equity ratio (avg) at times
3
With ROE of 2.66%, it has a expensive valuation with a 9.51 Price to Book Value
Stock DNA
Pharmaceuticals & Biotechnology
CNY 21,612 Million (Large Cap)
357.00
NA
0.00%
0.66
2.66%
9.51
Revenue and Profits:
Net Sales:
346 Million
(Quarterly Results - Jun 2025)
Net Profit:
5 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
25.03%
0%
25.03%
6 Months
35.02%
0%
35.02%
1 Year
99.93%
0%
99.93%
2 Years
66.59%
0%
66.59%
3 Years
399.48%
0%
399.48%
4 Years
612.5%
0%
612.5%
5 Years
577.62%
0%
577.62%
Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-2.59%
EBIT Growth (5y)
24.16%
EBIT to Interest (avg)
0.63
Debt to EBITDA (avg)
7.97
Net Debt to Equity (avg)
0.67
Sales to Capital Employed (avg)
0.34
Tax Ratio
17.35%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
2.62%
ROE (avg)
1.50%
Valuation key factors
Factor
Value
P/E Ratio
357
Industry P/E
Price to Book Value
9.51
EV to EBIT
151.75
EV to EBITDA
106.65
EV to Capital Employed
6.11
EV to Sales
17.65
PEG Ratio
13.39
Dividend Yield
NA
ROCE (Latest)
4.03%
ROE (Latest)
2.66%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
Bearish
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
346.50
351.20
-1.34%
Operating Profit (PBDIT) excl Other Income
44.50
42.70
4.22%
Interest
20.40
21.20
-3.77%
Exceptional Items
-0.00
-2.50
100.00%
Consolidate Net Profit
5.30
3.20
65.62%
Operating Profit Margin (Excl OI)
81.80%
71.50%
1.03%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is -1.34% vs -15.76% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is 65.62% vs -11.11% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
1,312.70
1,462.70
-10.26%
Operating Profit (PBDIT) excl Other Income
202.90
198.70
2.11%
Interest
82.80
83.80
-1.19%
Exceptional Items
0.30
1.30
-76.92%
Consolidate Net Profit
56.00
43.20
29.63%
Operating Profit Margin (Excl OI)
103.20%
84.50%
1.87%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -10.26% vs 0.24% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 29.63% vs 47.95% in Dec 2023
About Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd. 
Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






